TY - JOUR
T1 - Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy
T2 - The together retrospective study
AU - Buti, Sebastiano
AU - Bersanelli, Melissa
AU - Viansone, Alessandro
AU - Leonetti, Alessandro
AU - Masini, Cristina
AU - Ratta, Raffaele
AU - Procopio, Giuseppe
AU - Maines, Francesca
AU - Iacovelli, Roberto
AU - Ciccarese, Chiara
AU - Vitale, Maria Giuseppa
AU - De Giorgi, Ugo
AU - Mucciarini, Claudia
AU - Maruzzo, Marco
AU - Prati, Giuseppe
AU - Lattanzi, Elisabetta
AU - Ciammella, Patrizia
AU - Bruni, Alessio
AU - Andreani, Stefano
AU - D'Abbiero, Nunziata
PY - 2020
Y1 - 2020
N2 - Objectives: stereotactic body radiation therapy (SBRT) use has increased overtime for the management of metastatic renal cell carcinoma (mRCC) patients, with a likely good control of irradiated lesions. We planned a retrospective multicenter Italian study, with the aim of investigating the outcome of treatment with SBRT for non-brain secondary lesions in mRCC patients. Methods: all consecutive metastatic non-brain lesions from mRCC that underwent SBRT at nine Italian institutions from January 2015 to June 2017 were considered. The primary endpoint of the study was the lesion-PFS, calculated from SBRT initiation to the local progression of the irradiated lesion. Results: 57 extracranial metastatic lesions from 48 patients with primary mRCC were treated with SBRT. At the median follow-up of 26.4 months, the median lesion-PFS was not reached (43 censored); 72.4% of lesions were progression-free at 40 months, with significantly better lesion-PFS for small metastatic lesions (<14 mm). SBRT was safe and the 1-year local disease control was 87.7%. After SBRT, 18 patients (37.5%) permanently interrupted systemic therapy. Conclusions: consistently with the previous literature, our findings support the use of SBRT in selected mRCC patients.
AB - Objectives: stereotactic body radiation therapy (SBRT) use has increased overtime for the management of metastatic renal cell carcinoma (mRCC) patients, with a likely good control of irradiated lesions. We planned a retrospective multicenter Italian study, with the aim of investigating the outcome of treatment with SBRT for non-brain secondary lesions in mRCC patients. Methods: all consecutive metastatic non-brain lesions from mRCC that underwent SBRT at nine Italian institutions from January 2015 to June 2017 were considered. The primary endpoint of the study was the lesion-PFS, calculated from SBRT initiation to the local progression of the irradiated lesion. Results: 57 extracranial metastatic lesions from 48 patients with primary mRCC were treated with SBRT. At the median follow-up of 26.4 months, the median lesion-PFS was not reached (43 censored); 72.4% of lesions were progression-free at 40 months, with significantly better lesion-PFS for small metastatic lesions (<14 mm). SBRT was safe and the 1-year local disease control was 87.7%. After SBRT, 18 patients (37.5%) permanently interrupted systemic therapy. Conclusions: consistently with the previous literature, our findings support the use of SBRT in selected mRCC patients.
KW - Extra-cranial
KW - Metastatic renal cell carcinoma
KW - Oligometastatic
KW - Oligoprogressive
KW - RCC
KW - SBRT
KW - Stereotactic radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85074154595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074154595&partnerID=8YFLogxK
U2 - 10.1016/j.ctarc.2019.100161
DO - 10.1016/j.ctarc.2019.100161
M3 - Article
C2 - 31677494
AN - SCOPUS:85074154595
VL - 22
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
SN - 2213-0896
M1 - 100161
ER -